Search Results - "Nitz, Ulrike A"

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment by Gluz, Oleg, Nitz, Ulrike A, Christgen, Matthias, Kates, Ronald E, Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H, Harbeck, Nadia

“…The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only a few…”
Get full text

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer by Nitz, Ulrike A., Gluz, Oleg, Kümmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E., Gräser, Monika, Würstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H., Harbeck, Nadia

“…PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206 ; n = 5,625 registered) is the first trial combining the 21-gene…”
Get full text

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial by Harbeck, Nadia, Nitz, Ulrike A, Christgen, Matthias, Kümmel, Sherko, Braun, Michael, Schumacher, Claudia, Potenberg, Jochem, Tio, Joke, Aktas, Bahriye, Forstbauer, Helmut, Grischke, Eva-Maria, Scheffen, Iris, Malter, Wolfram, von Schumann, Raquel, Just, Marianne, Zu Eulenburg, Christine, Biehl, Claudia, Kolberg-Liedtke, Cornelia, Deurloo, Regula, de Haas, Sanne, Jóźwiak, Katarzyna, Hauptmann, Michael, Kates, Ronald, Graeser, Monika, Wuerstlein, Rachel, Kreipe, Hans H, Gluz, Oleg

“…Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective of the…”
Get full text

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial by Gluz, Oleg, Nitz, Ulrike A, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Schumacher, Johannes, Hartkopf, Andreas, Potenberg, Jochem, Lüedtke-Heckenkamp, Kerstin, Just, Marianne, Schem, Christian, von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Eulenburg, Christine Zu, Schinköthe, Timo, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC)…”
Get more information

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials by BERRY, Donald A, UENO, Naoto T, BERGH, Jonas, NITZ, Ulrike A, GIANNI, Alessandro M, BASSER, Russell L, ZANDER, Axel R, COOMBES, R. Charles, ROCHE, Henri, TOKUDA, Yutaka, DE VRIES, Elisabeth G. E, HORTOBAGYI, Gabriel N, JOHNSON, Marcella M, CROWN, John P, PEDRAZZOLI, Paolo, BREGNI, Marco, DEMIRER, Taner, XIUDONG LEI, CAPUTO, Jean, RODENHUIS, Sjoerd, PETERS, William P, LEONARD, Robert C, BARLOW, William E, TALLMAN, Martin S

“…Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to…”
Get full text

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer by Nitz, Ulrike A, Gluz, Oleg, Kümmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E, Gräser, Monika, Würstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H, Harbeck, Nadia

“…To our knowledge, WSG-ADAPT-HR+/HER2- (NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and…”
Get full text

Response by Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike A, Runnebaum, Ingo B, Hinke, Axel, Kreienberg, Rolf, Untch, Michael

Get full text

Response by Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike A, Runnebaum, Ingo B, Hinke, Axel, Kreienberg, Rolf, Untch, Michael

Get full text